Low-dose steroids for septic shock and severe sepsis: the use of Bayesian statistics to resolve clinical trial controversies

被引:53
作者
Kalil, Andre C. [1 ]
Sun, Junfeng [2 ]
机构
[1] Univ Nebraska Med Ctr, Dept Med, Omaha, NE 68198 USA
[2] NIH, Dept Crit Care Med, Bethesda, MD 20892 USA
关键词
Steroids; Sepsis; Shock; OXIDE SYNTHASE INHIBITOR; DOUBLE-BLIND; HYDROCORTISONE THERAPY; CORTICOSTEROIDS; EFFICACY; INFUSION; RECOMMENDATIONS; METAANALYSIS; PNEUMONIA; MORTALITY;
D O I
10.1007/s00134-010-2121-0
中图分类号
R4 [临床医学];
学科分类号
100218 [急诊医学];
摘要
Low-dose steroids have shown contradictory results in trials and three recent meta-analyses. We aimed to assess the efficacy and safety of low-dose steroids for severe sepsis and septic shock by Bayesian methodology. Randomized trials from three published meta-analyses were reviewed and entered in both classic and Bayesian databases to estimate relative risk reduction (RRR) for 28-day mortality, and relative risk increase (RRI) for shock reversal and side effects. In septic shock trials only (Marik meta-analysis; N = 965), the probability that low-dose steroids decrease mortality by more than 15% (i.e., RRR > 15%) was 0.41 (0.24 for RRR > 20% and 0.14 for RRR > 25%). For severe sepsis and septic shock trials combined, the results were as follows: (1) for the Annane meta-analysis (N = 1,228), the probabilities were 0.57 (RRR > 15%), 0.32 (RRR > 20%), and 0.13 (RRR > 25%); (2) for the Minneci meta-analysis (N = 1,171), the probability was 0.57 to achieve mortality RRR > 15%, 0.32 (RRR > 20%), and 0.14 (RRR > 25%). The removal of the Sprung trial from each analysis did not change the overall results. The probability of achieving shock reversal ranged from 65 to 92%. The probability of developing steroid-induced side effects was as follows: for gastrointestinal bleeding (N = 924), there was a 0.73 probability of steroids causing an RRI > 1%, 0.70 for RRI > 2%, and 0.67 for RRI > 5%; for superinfections (N = 964), probabilities were 0.81 (RRI > 1%), 0.76 (RRI > 2%), and 0.70 (RRI > 5%); and for hyperglycemia (N = 540), 0.99 (RRI > 1%), 0.97 (RRI > 2%), and 0.94 (RRI > 5%). Based on clinically meaningful thresholds (RRR > 15-25%) for mortality reduction in severe sepsis or septic shock, the Bayesian approach to all three meta-analyses consistently showed that low-dose steroids were not associated with survival benefits. The probabilities of developing steroid-induced side effects (superinfections, bleeding, and hyperglycemia) were high for all analyses.
引用
收藏
页码:420 / 429
页数:10
相关论文
共 49 条
[1]
Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock [J].
Annane, D ;
Sébille, V ;
Charpentier, C ;
Bollaert, PE ;
François, B ;
Korach, JM ;
Capellier, G ;
Cohen, Y ;
Azoulay, E ;
Troché, G ;
Chaumet-Riffaut, P ;
Bellissant, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (07) :862-871
[2]
Inappropriate sympathetic activation at onset of septic shock - A spectral analysis approach [J].
Annane, D ;
Trabold, F ;
Sharshar, T ;
Jarrin, I ;
Blanc, AS ;
Raphael, JC ;
Gajdos, P .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 160 (02) :458-465
[3]
Corticosteroids in the Treatment of Severe Sepsis and Septic Shock in Adults A Systematic Review [J].
Annane, Djillali ;
Bellissant, Eric ;
Bollaert, Pierre-Edouard ;
Briegel, Josef ;
Confalonieri, Marco ;
De Gaudio, Raffaele ;
Keh, Didier ;
Kupfer, Yizhak ;
Oppert, Michael ;
Meduri, G. Umberto .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (22) :2362-2375
[4]
Early blood glucose control and mortality in critically ill patients in Australia [J].
Bagshaw, Sean M. ;
Egi, Moritoki ;
George, Carol ;
Bellomo, Rinaldo .
CRITICAL CARE MEDICINE, 2009, 37 (02) :463-470
[5]
Administration of the nitric oxide synthase inhibitor NG-Methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis:: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002) [J].
Bakker, J ;
Grover, R ;
McLuckie, A ;
Holzapfel, L ;
Andersson, J ;
Lodato, R ;
Watson, D ;
Grossman, S ;
Donaldson, J ;
Takala, J .
CRITICAL CARE MEDICINE, 2004, 32 (01) :1-12
[6]
Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[7]
Reversal of late septic shock with supraphysiologic doses of hydrocortisone [J].
Bollaert, PE ;
Charpentier, C ;
Levy, B ;
Debouverie, M ;
Audibert, G ;
Larcan, A .
CRITICAL CARE MEDICINE, 1998, 26 (04) :645-650
[8]
Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study [J].
Briegel, J ;
Forst, H ;
Haller, M ;
Schelling, G ;
Kilger, E ;
Kuprat, G ;
Hemmer, B ;
Hummel, T ;
Lenhart, A ;
Heyduck, M ;
Stoll, C ;
Peter, K .
CRITICAL CARE MEDICINE, 1999, 27 (04) :723-732
[9]
Center for Drug Evaluation and Research (CDER), 2005, REV GUID COND CLIN S
[10]
Hydrocortisone reverses refractory septic shock [J].
Chawla, K ;
Kupfer, Y ;
Goldman, I ;
Tessler, S .
CRITICAL CARE MEDICINE, 1999, 27 (01) :A33-A33